Table 3 Patient characteristics and treatment status
From: Changes in tear volume and ocular symptoms of patients receiving oral anticancer drug S-1
Watering eyes | No watering eyes | P | |||||
|---|---|---|---|---|---|---|---|
n = 6 | n = 5 | ||||||
Age | (year) | 70 | (44–80) | 63 | (43–67) | 0.297* | |
Sex | (male/female) | 6 | (3/3) | 5 | (3/2) | 1.000** | |
Height | (cm) | 156.15 | (147.0–178.0) | 146.2 | (154.3–164.0) | 0.535* | |
Body weight | (Kg) | 46.75 | (40.0–58.8) | 47.6 | (31.2–78.4) | 0.548* | |
BSA | (m2) | 1.372 | (1.29–1.69) | 1.404 | (1.16–1.79) | 0.548* | |
Scr | (mg/dL) | 0.61 | (0.43–0.98) | 0.6 | (0.49–0.80) | 0.575* | |
Dose | Start | (mg) | 100 | (80–120) | 100 | (80–120) | 0.535* |
Total | (mg) | 13,440 | (4880–19,790) | 13,440 | (5820–22,360) | 0.548* | |
Therapeutic intensity | RDI | (%) | 82.68 | (49.11–99.41) | 79.95 | (54.34–95.14) | 0.522* |
Treatment period | Course | 7 | (2–8) | 8 | (2–8) | 0.382* | |
Days | 319 | (84–350) | 350 | (91–371) | 0.601* | ||